Objective:To identify the acceptance of the vaccine based on factors influencing the vaccination program and the side effects from vaccinated people.Methods:A cross-sectional online survey of 1529 Bangladeshi adults(...Objective:To identify the acceptance of the vaccine based on factors influencing the vaccination program and the side effects from vaccinated people.Methods:A cross-sectional online survey of 1529 Bangladeshi adults(≥18 years)was conducted between 17 April,2021 and 26 April,2021.Statistical analysis of the data included Chi-square test and multinomial logistic regression analysis.Results:In total,67.04%of the participants were willing to accept a COVID-19 vaccine,and 45.00%of them in our study had already received.Overall Bangladeshi people were more likely to accept COVID-19 vaccine if the vaccine reduces risk of infectious disease and has no associated health risk after receiving it.Among the respondents,religions,education level,living area(urban),belif that vaccines protect against infectious diseases and vaccines do not have health-related risk and vaccination was significantly associated with the acceptance of COVID-19 vaccines.Conversely,people’s perception on development of natural immunity rather than receiving vaccines was also positively reflected.More than half(57.41%)reported minor side effects such as fever,muscle pain and headache after getting vaccine shots.Conclusions:This study revealed that the acceptance rate was influenced by socio-demographic and health-related characteristics and people are not afraid of this vaccine if they faced minor side effects after receiving it.These findings might help the government and policymakers of Bangladesh to implement necessary steps to accomplish this vaccination program effectively.展开更多
Objective: The aim of the study was to observe the clinical effects of Shenqi Fuzheng injection decreasing sideeffects of chemotherapy for patients with ovarian epithelial cancer. Methods: The 36 cases of ovarian epit...Objective: The aim of the study was to observe the clinical effects of Shenqi Fuzheng injection decreasing sideeffects of chemotherapy for patients with ovarian epithelial cancer. Methods: The 36 cases of ovarian epithelial cancer in The Third Affiliated Hospital of SUN Yat-sen University(Guangzhou, China) from June 2010 to June 2013, were randomly divided into the study group and the control group. The study group contained 18 cases using Shenqi Fuzheng injection combined with TP(Taxol + Carboplatin/cisplatin) chemotherapy, and the control group contained 18 cases only using TP chemotherapy without Shenqi Fuzheng injection. During and after chemotherapy, the side-effects and therapy effects were observed. Results: The grade II of nausea and vomit were less in the study group than that in the control group, which was significantly different(P < 0.05). But there were no significantly differences in grade I of nausea and vomit between the two groups(P > 0.05). There was less degree of decrease of lymphocyte in the study group than that in the control group, which was significantly different(P < 0.05). But between two groups, there were no significant differences in the drop of white blood cells and red blood cells, the incidence of allergic reaction, liver and renal functions, nerve lesion and phalacrosis(P > 0.05). There was no significant difference in chemotherapy effect between the two groups(P > 0.05). Conclusion: Shenqi Fuzheng injection can in some degree relieve the side effects of TP chemotherapy for the patients with ovarian epithelial cancer, including relieving nausea and vomiting, protecting lymphocytes, and has no conflict effect on chemotherapy efficacy.展开更多
To observe the efficacy of Baofuxin for treatment of bleeding side effect induced by IUD. Method The study is a multi-center trial. The subjects were randomly allocated into two groups, Baofuxin group (90 cases) and...To observe the efficacy of Baofuxin for treatment of bleeding side effect induced by IUD. Method The study is a multi-center trial. The subjects were randomly allocated into two groups, Baofuxin group (90 cases) and Indomethacin group (90 cases). In the Baofuxin group, the subjects took the medicine on the first day of menses, once a bag, twice a day for 10 days. In the Indomethacin group,only one capsule was taken once a time, twice a day for 7 days. The treatment was given for three menstrual cycles. The subjects were asked to record their bleeding/spotting by using menstrual diary card not only during the treatment cycles but also during the three months previous and after the treatment cycles. The menstrual profile was analyzed by using MDSv2. 3 program that was provided by WHO. Results Within each 90-day reference period of treatment and post-treatment cycles, the number of bleeding/spotting days decreased obviously and bleeding/spotting free days were greatly increased. Both medicines have little effect on number of episode of bleeding/spotting. The subjects who thought the treatment were highly effective were 81. 1% in the Baofuxin group and 56.2% in the Indomethacin group respectively (P <0.01). Conclusion Both Bat,fuxin and indomethacin are highly effective on treatment of bleeding side effect induced by IUD, but Baofuxin had longer effects and was more acceptable.展开更多
目的:依据药物基因组学结果,探讨抗精神病药对首发精神分裂症患者疗效和药物不良反应的影响。方法:纳入2020年1月至2022年6月淮安市第三人民医院的首发精神分裂症患者,分为研究组和对照组各100例,研究组根据基因检测结果指导用药,对照...目的:依据药物基因组学结果,探讨抗精神病药对首发精神分裂症患者疗效和药物不良反应的影响。方法:纳入2020年1月至2022年6月淮安市第三人民医院的首发精神分裂症患者,分为研究组和对照组各100例,研究组根据基因检测结果指导用药,对照组依据医师经验用药,分别于治疗前、治疗后4、8、12、16周使用阳性和阴性症状量表(positive and negative syndrome scale,PANSS)、临床疗效总评量表(clinical global impression,CGI)评定疗效,威斯康星卡片分类测验(Wisconsin card classification tests,WCST)及个人和社会功能评估量表(personal and social function assessment scales,PSP)评定认知及社会功能,并在治疗前后和两组之间比较,同时评定药物副反应量表(treatment emergent symptom scale,TESS)及作实验室检查,了解药物不良反应。结果:两组患者治疗后的PANSS总分、CGI、TESS、PSP、WCST等评分均较治疗前显著改善(P<0.05或P<0.001),研究组患者明显好于对照组(P<0.05或P<0.001),治疗后12~16周肝功能损害也轻于对照组,差异均有统计学意义(P<0.05或P<0.001)。血常规等实验室结果两组间差异无统计学意义(P>0.05)。结论:应用基因检测可提高精神分裂症患者药物治疗临床效果,减少不良反应的发生,指导临床合理、精准用药和个体化治疗。展开更多
目的探讨药物基因组学检测结果应用对难治性精神分裂症患者疗效及药物不良反应的影响。方法选取2020年1月-2022年6月江苏省淮安市第三人民医院收治的100例难治性精神分裂症患者。依据基因检测结果指导用药,分别于治疗前、治疗4、8、12...目的探讨药物基因组学检测结果应用对难治性精神分裂症患者疗效及药物不良反应的影响。方法选取2020年1月-2022年6月江苏省淮安市第三人民医院收治的100例难治性精神分裂症患者。依据基因检测结果指导用药,分别于治疗前、治疗4、8、12、16周使用阳性阴性症状量表(positive and egative symptom scale,PANSS)、临床疗效总评量表(clinical global impression,CGI)评定临床疗效,威斯康星卡片分类测验及个人和社会功能评估量表(personal and social function assessment scales,PSP)分别评定认知及社会功能改善情况,同时使用药物副反应量表(treatment emergent symptom scale,TESS)及做血常规、肝功能、肾功能和心电图等检查,以了解药物不良反应。结果治疗4周PANSS评分为(59.62±6.29)分,治疗8周PANSS评分为(54.83±7.37)分,治疗12周PANSS评分为(49.34±7.93)分,治疗16周PANSS评分(44.68±8.73)分,均低于治疗前的(62.93±5.55)分(P<0.001);治疗4、8、12和16周的CGI、PSP、威斯康星卡片分类测验等评分均优于治疗前(P<0.001)。治疗16周TESS评定与治疗4周比较,差异有统计学意义(P<0.01),但血常规、心电图、脑电图、肝功能和肾功能检查异常与否与治疗前比较,差异无统计学意义(P>0.05)。结论应用基因检测可显著提高难治性精神分裂症患者的临床疗效,且并不增加不良反应,因此基因检测可促进该病的临床合理用药、精准用药和个体化治疗。展开更多
文摘Objective:To identify the acceptance of the vaccine based on factors influencing the vaccination program and the side effects from vaccinated people.Methods:A cross-sectional online survey of 1529 Bangladeshi adults(≥18 years)was conducted between 17 April,2021 and 26 April,2021.Statistical analysis of the data included Chi-square test and multinomial logistic regression analysis.Results:In total,67.04%of the participants were willing to accept a COVID-19 vaccine,and 45.00%of them in our study had already received.Overall Bangladeshi people were more likely to accept COVID-19 vaccine if the vaccine reduces risk of infectious disease and has no associated health risk after receiving it.Among the respondents,religions,education level,living area(urban),belif that vaccines protect against infectious diseases and vaccines do not have health-related risk and vaccination was significantly associated with the acceptance of COVID-19 vaccines.Conversely,people’s perception on development of natural immunity rather than receiving vaccines was also positively reflected.More than half(57.41%)reported minor side effects such as fever,muscle pain and headache after getting vaccine shots.Conclusions:This study revealed that the acceptance rate was influenced by socio-demographic and health-related characteristics and people are not afraid of this vaccine if they faced minor side effects after receiving it.These findings might help the government and policymakers of Bangladesh to implement necessary steps to accomplish this vaccination program effectively.
基金Supported by a grant of Chinese Medicine Scientific Research of Guangdong Province(No.2010113)
文摘Objective: The aim of the study was to observe the clinical effects of Shenqi Fuzheng injection decreasing sideeffects of chemotherapy for patients with ovarian epithelial cancer. Methods: The 36 cases of ovarian epithelial cancer in The Third Affiliated Hospital of SUN Yat-sen University(Guangzhou, China) from June 2010 to June 2013, were randomly divided into the study group and the control group. The study group contained 18 cases using Shenqi Fuzheng injection combined with TP(Taxol + Carboplatin/cisplatin) chemotherapy, and the control group contained 18 cases only using TP chemotherapy without Shenqi Fuzheng injection. During and after chemotherapy, the side-effects and therapy effects were observed. Results: The grade II of nausea and vomit were less in the study group than that in the control group, which was significantly different(P < 0.05). But there were no significantly differences in grade I of nausea and vomit between the two groups(P > 0.05). There was less degree of decrease of lymphocyte in the study group than that in the control group, which was significantly different(P < 0.05). But between two groups, there were no significant differences in the drop of white blood cells and red blood cells, the incidence of allergic reaction, liver and renal functions, nerve lesion and phalacrosis(P > 0.05). There was no significant difference in chemotherapy effect between the two groups(P > 0.05). Conclusion: Shenqi Fuzheng injection can in some degree relieve the side effects of TP chemotherapy for the patients with ovarian epithelial cancer, including relieving nausea and vomiting, protecting lymphocytes, and has no conflict effect on chemotherapy efficacy.
文摘To observe the efficacy of Baofuxin for treatment of bleeding side effect induced by IUD. Method The study is a multi-center trial. The subjects were randomly allocated into two groups, Baofuxin group (90 cases) and Indomethacin group (90 cases). In the Baofuxin group, the subjects took the medicine on the first day of menses, once a bag, twice a day for 10 days. In the Indomethacin group,only one capsule was taken once a time, twice a day for 7 days. The treatment was given for three menstrual cycles. The subjects were asked to record their bleeding/spotting by using menstrual diary card not only during the treatment cycles but also during the three months previous and after the treatment cycles. The menstrual profile was analyzed by using MDSv2. 3 program that was provided by WHO. Results Within each 90-day reference period of treatment and post-treatment cycles, the number of bleeding/spotting days decreased obviously and bleeding/spotting free days were greatly increased. Both medicines have little effect on number of episode of bleeding/spotting. The subjects who thought the treatment were highly effective were 81. 1% in the Baofuxin group and 56.2% in the Indomethacin group respectively (P <0.01). Conclusion Both Bat,fuxin and indomethacin are highly effective on treatment of bleeding side effect induced by IUD, but Baofuxin had longer effects and was more acceptable.
文摘目的:依据药物基因组学结果,探讨抗精神病药对首发精神分裂症患者疗效和药物不良反应的影响。方法:纳入2020年1月至2022年6月淮安市第三人民医院的首发精神分裂症患者,分为研究组和对照组各100例,研究组根据基因检测结果指导用药,对照组依据医师经验用药,分别于治疗前、治疗后4、8、12、16周使用阳性和阴性症状量表(positive and negative syndrome scale,PANSS)、临床疗效总评量表(clinical global impression,CGI)评定疗效,威斯康星卡片分类测验(Wisconsin card classification tests,WCST)及个人和社会功能评估量表(personal and social function assessment scales,PSP)评定认知及社会功能,并在治疗前后和两组之间比较,同时评定药物副反应量表(treatment emergent symptom scale,TESS)及作实验室检查,了解药物不良反应。结果:两组患者治疗后的PANSS总分、CGI、TESS、PSP、WCST等评分均较治疗前显著改善(P<0.05或P<0.001),研究组患者明显好于对照组(P<0.05或P<0.001),治疗后12~16周肝功能损害也轻于对照组,差异均有统计学意义(P<0.05或P<0.001)。血常规等实验室结果两组间差异无统计学意义(P>0.05)。结论:应用基因检测可提高精神分裂症患者药物治疗临床效果,减少不良反应的发生,指导临床合理、精准用药和个体化治疗。
文摘目的探讨药物基因组学检测结果应用对难治性精神分裂症患者疗效及药物不良反应的影响。方法选取2020年1月-2022年6月江苏省淮安市第三人民医院收治的100例难治性精神分裂症患者。依据基因检测结果指导用药,分别于治疗前、治疗4、8、12、16周使用阳性阴性症状量表(positive and egative symptom scale,PANSS)、临床疗效总评量表(clinical global impression,CGI)评定临床疗效,威斯康星卡片分类测验及个人和社会功能评估量表(personal and social function assessment scales,PSP)分别评定认知及社会功能改善情况,同时使用药物副反应量表(treatment emergent symptom scale,TESS)及做血常规、肝功能、肾功能和心电图等检查,以了解药物不良反应。结果治疗4周PANSS评分为(59.62±6.29)分,治疗8周PANSS评分为(54.83±7.37)分,治疗12周PANSS评分为(49.34±7.93)分,治疗16周PANSS评分(44.68±8.73)分,均低于治疗前的(62.93±5.55)分(P<0.001);治疗4、8、12和16周的CGI、PSP、威斯康星卡片分类测验等评分均优于治疗前(P<0.001)。治疗16周TESS评定与治疗4周比较,差异有统计学意义(P<0.01),但血常规、心电图、脑电图、肝功能和肾功能检查异常与否与治疗前比较,差异无统计学意义(P>0.05)。结论应用基因检测可显著提高难治性精神分裂症患者的临床疗效,且并不增加不良反应,因此基因检测可促进该病的临床合理用药、精准用药和个体化治疗。
